Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With BenralizumabRecruiting
NCT06862206N/AUpdated Jul 22, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
China
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.Recruiting
NCT06542250Phase 1, Phase 2Updated Jul 21, 2026
Sponsor: AstraZeneca
B-cell Malignancies
United States, Australia, Canada, China, Denmark +5 more
Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.Not Yet Recruiting
NCT07717450Phase 3Updated Jul 21, 2026
Sponsor: UNICANCER
Metastatic Invasive Breast Cancer
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)Recruiting
NCT07717840Phase 1, Phase 2Updated Jul 21, 2026
Sponsor: AstraZeneca
RSV Respiratory Syncytial Virus
United States
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in RussiaTerminated
NCT07247292N/AUpdated Jul 21, 2026
Sponsor: AstraZeneca
Rare Diseases · Neuromyelitis Optica Spectrum Disorder (NMOSD)
Russia
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of ExacerbationsRecruiting
NCT07566195Phase 3Updated Jul 21, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease · COPD
France
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationRecruiting
NCT06952803Phase 3Updated Jul 21, 2026
Sponsor: AstraZeneca
Prostate Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenRecruiting
NCT05624450Phase 3Updated Jul 21, 2026
Sponsor: AstraZeneca
Viral Lung Infection and Acute Respiratory Failure
United States, Argentina, Australia, Belgium, Brazil +34 more
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersRecruiting
NCT06594068Phase 4Updated Jul 21, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerRecruiting
NCT04918186Phase 2Updated Jul 21, 2026
Sponsor: Canadian Cancer Trials Group
Ovarian Cancer
United States, Canada
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)Recruiting
NCT06996782Phase 1, Phase 2Updated Jul 21, 2026
Sponsor: AstraZeneca
Advanced or Metastatic Non-small Cell Lung Cancer
United States, Belgium, Brazil, China, France +15 more
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCActive Not Recruiting
NCT01933932Phase 3Updated Jul 21, 2026
Sponsor: AstraZeneca
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
United States, Argentina, Australia, Austria, Belgium +21 more
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerRecruiting
NCT07218809Phase 3Updated Jul 21, 2026
Sponsor: AstraZeneca
Epithelial Ovarian Cancer
United States, Australia, Belgium, Brazil, Canada +19 more
A Trial to Investigate Benralizumab in Children With Eosinophilic DiseasesRecruiting
NCT06512883Phase 3Updated Jul 21, 2026
Sponsor: AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis (EGPA) · Hypereosinophilia Syndrome (HES)
United States, Brazil, Canada, France, India +5 more
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in ItalyActive Not Recruiting
NCT06948396N/AUpdated Jul 20, 2026
Sponsor: AstraZeneca
Asthma
Italy
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive Not Recruiting
NCT03833154Phase 3Updated Jul 20, 2026
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
United States, Australia, Belgium, Brazil, Canada +15 more
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaRecruiting
NCT07088991N/AUpdated Jul 20, 2026
Sponsor: AstraZeneca
Neurofibromatosis
Russia
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)Active Not Recruiting
NCT07128615Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: AstraZeneca
Influenza A
United States
A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityCompleted
NCT06595238Phase 2Updated Jul 20, 2026
Sponsor: AstraZeneca
Obesity or Overweight
United States, Australia, Canada, Japan, United Kingdom
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruiting
NCT06564038Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukaemia · Small Lymphocytic Lymphoma · Mantle-cell Lymphoma · Large B-cell Lymphoma
United States, Australia, China, Czechia, Denmark +8 more
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX OverexpressionRecruiting
NCT07155226Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: AstraZeneca
Acute Lymphoblastic Leukaemia · Acute Myeloid Leukaemia · Higher-risk Myelodysplastic Syndromes
United States, Australia, Canada, Denmark, Germany +4 more
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsRecruiting
NCT06549595Phase 3Updated Jul 20, 2026
Sponsor: AstraZeneca
Untreated Follicular Lymphoma
United States, Australia, Belgium, Brazil, Canada +18 more
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruiting
NCT05774951Phase 3Updated Jul 20, 2026
Sponsor: AstraZeneca
Breast Cancer, Early Breast Cancer
United States, Argentina, Australia, Austria, Belgium +34 more
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerRecruiting
NCT06727227N/AUpdated Jul 20, 2026
Sponsor: AstraZeneca
Breast Cancer
Bulgaria, Slovenia
Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)Recruiting
NCT07113223NAUpdated Jul 20, 2026
Sponsor: Idoven 1903 S.L.
Heart Failure · Cardiovascular Risk Factors
Spain, Sweden

Previous page Next page